10q10k10q10k.net
BioAtla, Inc.

BioAtla, Inc.BCABEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

BioAtla, Inc. is a clinical-stage biotechnology company specializing in developing proprietary conditionally active biologic therapies focused on oncology indications. Its pipeline includes multiple lead candidates targeting solid tumors, with operations centered on advancing clinical trials to deliver treatments to patients worldwide.

Q3 2023Q2 2023Q1 2023Q3 2022Q2 2022Q1 2022

BCAB Q3 FY2023 Key Financial Metrics

Revenue

$0

Gross Profit

N/A

Operating Profit

$-35.0M

Net Profit

$-33.3M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-0.70

BioAtla, Inc. Q3 FY2023 Financial Summary

BioAtla, Inc. reported revenue of $0 for Q3 FY2023, with a net profit of $-33.3M (down 29.3% YoY) (N/A margin).

Key Financial Metrics

Total Revenue$0
Net Profit$-33.3M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ3 FY2023

BioAtla, Inc. Quarterly Revenue & Net Profit History

BioAtla, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q3 FY2023$0—$-33.3MN/A
Q2 FY2023$0—$-35.8MN/A
Q1 FY2023$0—$-27.5MN/A
Q3 FY2022$0—$-25.8MN/A
Q2 FY2022$0—$-28.9MN/A
Q1 FY2022$0—$-24.3MN/A

Income Statement

Q1 2022Q2 2022Q3 2022Q1 2023Q2 2023Q3 2023
Revenue$0$0$0$0$0$0
YoY GrowthN/AN/AN/AN/AN/AN/A

Balance Sheet

Q1 2022Q2 2022Q3 2022Q1 2023Q2 2023Q3 2023
Assets$230.7M$213.5M$189.1M$204.6M$179.6M$151.4M
Liabilities$40.6M$48.5M$46.5M$48.1M$55.1M$56.7M
Equity$190.1M$165.0M$142.6M$156.4M$124.5M$94.7M

Cash Flow

Q1 2022Q2 2022Q3 2022Q1 2023Q2 2023Q3 2023
Operating CF$-25.1M$-16.9M$-24.0M$-22.7M$-24.1M$-27.3M